Elemental impurity risk management can help biomanufacturers to maintain regulatory alignment and ensure patient safety.
FDA inspectors last month spent two weeks inspecting the plant of the Chinese API maker after learning its valsartan contained an impurity that is a suspected carcinogen. Inspectors had been in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback